In statistics, showing a significant difference between observed results in two groups is distinct from the predictive power of that observation.

Alexion Inc. maintains that it was appropriate to do a statistical analysis of a handful of patients in a Phase I trial of its 5G1.1 C5 complement inhibitor in lupus, while acknowledging that its ability to predict future results based on those small numbers is limited. But